Jordan Gauthier
Overview
Explore the profile of Jordan Gauthier including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
66
Citations
1616
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Portuguese A, Huang J, Jeon Y, Taheri M, Albittar A, Liang E, et al.
Haematologica
. 2025 Mar;
PMID: 40079097
Lisocabtagene maraleucel (liso-cel) and axicabtagene ciloleucel (axi-cel) are FDA- and EMAapproved chimeric antigen receptor (CAR) T-cell therapies for relapsed/refractory large B-cell lymphoma (LBCL). However, comparative real-world analyses of their efficacy...
2.
Samples L, Sadrzadeh H, Frigault M, Jacobson C, Hamadani M, Gurumurthi A, et al.
Blood
. 2025 Feb;
PMID: 39938007
Burkitt lymphoma (BL) is an aggressive B-cell lymphoma associated with poor outcomes in patients with relapsed/refractory disease. This multicenter, retrospective study evaluated real-world CD19 CAR T-cell therapy outcomes in patients...
3.
Gauthier J, Liang E, Huang J, Kimble E, Hirayama A, Fiorenza S, et al.
Blood Adv
. 2025 Jan;
PMID: 39820359
CD19-directed chimeric antigen receptor-engineered (CD19 CAR) T-cell therapy elicits high response rates but fails to induce durable responses in most adults with relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia...
4.
Liang E, Huang J, Portuguese A, Ortiz-Maldonado V, Albittar A, Wuliji N, et al.
Blood Adv
. 2024 Dec;
9(3):606-616.
PMID: 39626349
Immune effector cell-associated hematotoxicity (ICAHT) is associated with morbidity and mortality after chimeric antigen receptor (CAR) T-cell therapy. To date, the factors associated with ICAHT are poorly characterized, and there...
5.
Liang E, Rejeski K, Fei T, Albittar A, Huang J, Portuguese A, et al.
Bone Marrow Transplant
. 2024 Nov;
60(2):254.
PMID: 39533017
No abstract available.
6.
Shah B, Mattison R, Abboud R, Abdelmessieh P, Aldoss I, Burke P, et al.
J Natl Compr Canc Netw
. 2024 Oct;
22(8):563-576.
PMID: 39413812
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for acute lymphoblastic leukemia (ALL) provide recommendations for management of ALL, with a focus on the classification of ALL subtypes based...
7.
Torabi A, Love J, Hyun T, Pham A, Gauthier J, Hirayama A, et al.
J Hematop
. 2024 Aug;
17(4):259-264.
PMID: 39186243
Targeted immunotherapy is a promising approach in treating high-risk and refractory/relapsed lymphoid malignancies. Although this strategy has shown a significant success in treating non-Hodgkin B-cell lymphomas and plasma cell myeloma,...
8.
Rosen E, Krantz E, McCulloch D, Wilson M, Tverdek F, Kassamali Escobar Z, et al.
Transplant Cell Ther
. 2024 Aug;
30(11):1108.e1-1108.e11.
PMID: 39179107
Recipients of cellular therapies, including hematopoietic cell transplant (HCT) and chimeric antigen receptor T-cell (CART) therapy, are at risk for poor outcomes from coronavirus disease 2019 (COVID-19). There are limited...
9.
Hirayama A, Wright J, Smythe K, Fiorenza S, Shaw A, Gauthier J, et al.
Hemasphere
. 2024 Aug;
8(8):e142.
PMID: 39113729
CD19-targeted chimeric antigen receptor T-cell (CAR-T) immunotherapy has transformed the management of relapsed/refractory large B-cell lymphoma (LBCL), yet durable remissions are observed in less than half of treated patients. The...
10.
Bodansky A, Yu D, Rallistan A, Kalaycioglu M, Boonyaratanakornkit J, Green D, et al.
J Clin Invest
. 2024 May;
134(13).
PMID: 38753445
Given the global surge in autoimmune diseases, it is critical to evaluate emerging therapeutic interventions. Despite numerous new targeted immunomodulatory therapies, comprehensive approaches to apply and evaluate the effects of...